Infusion Device Used for Treating Diabetes

A new infusion device uses intracellular activation therapy (iCAT) for the treatment of Type 1 and Type 2 diabetes.

The iCAT therapy treats diabetes by addressing its core problem: improper fat metabolism. By treating this problem, the system is able to achieve the stabilization of diabetes complications, and in many cases, the reversal of secondary complications of both Type 1 and Type 2 diabetes. The iCAT utilizes a specially designed insulin delivery pump with proprietary algorithms, which delivers small micro-doses of insulin in a pattern that mimics the way a normal pancreas secretes insulin, which is then used by the liver. Intracellular activation therapy also uses real-time measurements of the patient's blood sugar levels and body-wide metabolic rate using a metabolic measurement cart. This data is transmitted to the pump, which automatically adjusts the next insulin dosage to stimulate a more normal metabolism. The metabolic cart also measures exhaled CO2 in the patient's breath, to determine the ‘reactivation' of normal metabolism in the patient as a result of the therapy. With normalization of liver enzyme functions, the body's cells begin to utilize glucose, something that people with diabetes cannot do normally. This treatment restores the optimum metabolism levels, which promotes healing. The iCAT system was developed by VitalCare Diabetes Treatment Centers (Carson City, NV, USA), and approved by the U.S. Food and Drug Administration (FDA).

"With the only FDA approved device delivering this treatment, we will expect to sign agreements to start the establishment of iCAT treatment centers immediately,” said Jimmy McDougald, CEO of VitalCare. "This is a major factor in the establishment of our treatment centers, as we begin to move iCAT into the commercial market.”

Vitalcare is planning to market the technology in licensed "VitalCare Diabetes Treatment Centers.” Currently, there are approximately 30 licensed iCAT clinics operating in North America, including Florida, Arizona, Utah, California, Texas, and Nevada, and anticipates having further clinics opened, which will be either company owned, joint venture, or sub-licensed affiliates, in all fifty states of the U.S. by 2010.


Related Links:
VitalCare Diabetes Treatment Centers